

Performance (consolidated)

(¥ million)

	2016 (JGAAP)	2017 (JGAAP)	2018 (JGAAP)	2019 (JGAAP)	2020 (IFRS)	2021 (IFRS)	2022 (IFRS) (estimated)
Revenue	98,781	101,448	114,716	116,637	121,859	137,484	141,000
Operating profit	15,280	17,079	20,644	21,668	27,202	32,948	30,000
Profit before tax	16,244	17,451	21,540	22,442	27,608	33,301	30,400
Profit attributable to owners of parent	11,749	12,953	16,302	16,866	19,540	24,986	24,000

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2020 (IFRS)	Sales 2021 (IFRS)	Sales 2022	
						Apr.-Sep.	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	15,350	18,338	9,139	14,600
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	2,387	7,750	6,856	14,700
				(Japan)	(1,953)	(4,059)	(2,090)
(U.S.)				(434)	(3,691)	(4,765)	(10,200)
Upravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	6,804	8,400	4,921	10,300
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,906	6,770	2,997	5,500
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-2018	5,312	5,300	2,618	5,400
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	6,743	4,106	1,470	2,700
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,677	2,532	1,439	2,850
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	5,474	4,563	1,392	2,500
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	1,970	2,128	1,259	2,900
Erizas	dexamethasone cipeclate	allergic rhinitis	Dec-2009	2,444	2,330	674	2,400
Profit in co-promotion				8,442	8,934	5,005	9,500
Revenues from the licensing of industrial property rights				24,338	33,207	14,469	30,200
Pharmaceuticals				106,478	120,650	60,499	119,500
Functional Food				15,380	16,834	10,637	21,500
Revenue				121,859	137,484	71,136	141,000